Yunkang Group (02325) announced its interim results, reporting a profit attributable to shareholders of RMB 2.444 million, marking a turnaround from loss to profit year-on-year.

Yunkang Group (02325) announced its interim results for the six months ended June 30, 2026. The group's revenue amounted to RMB 253 million, a year-on-year decrease of 19.3%. Profit attributable to shareholders was RMB 2.444 million, marking a turnaround from loss to profit compared to the same period last year. Earnings per share were RMB 0.004.

Zhitong FinanceAug 28 21:19

YUNKANG GROUP: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026

HKEXAug 28 20:17

The underlying logic for innovative drugs and CXO has fully shifted toward "performance validation." Wuxi XDC shares surged more than 12% following its earnings release.

1. How do institutions interpret the recent trends in the innovative drug and CXO sectors? 2. What were the core drivers behind Wuxi XDC's better-than-expected performance in the first half of the year?

cls.cnAug 25 13:40

Yunkang Group Sets August Board Meeting to Review Interim Results and Dividend

TipRanksAug 18 17:23

YUNKANG GROUP: DATE OF BOARD MEETING

HKEXAug 18 16:42

Dual catalysts of innovative drugs going global and accelerated policy support drive strong gains across Hong Kong-listed biotech stocks, with Zhaoyan New Drug surging nearly 22%.

① What is the pass rate for the formal review of innovative drugs under the National Reimbursement Drug List (NRDL) and commercial insurance in 2026? ② How have outbound licensing deals for China’s innovative drugs performed in the first half of this year?

cls.cnJul 15 11:30